Ipilimumab, a Pioneer Breakthrough in Cancer Treatment - Forbes
May 20, 2024 · Although initially designed to treat advanced melanoma, doctors today may offer ipilimumab and other checkpoint inhibitors to treat several types of cancers. This article describes how...
BMS-986253 Plus Nivolumab/Ipilimumab Fails to Boost …
1 day ago · The addition of the anti–interleukin 8 (IL-8) monoclonal antibody BMS-986253 to nivolumab (Opdivo) and ipilimumab (Yervoy) did not lead to an improvement in responses or progression-free ...
Pre- and post-surgical immunotherapy improves outcomes for …
May 15, 2024 · Mar. 16, 2023 — In a Phase II trial, adding ipilimumab to a neoadjuvant, or pre-surgical, combination of nivolumab plus platinum-based chemotherapy, resulted in a major pathologic response (MPR...
Study finds increased survival with nivolumab plus ipilimumab vs.
Dec 9, 2024 · For patients with microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal cancer who had not previously received systemic treatment, progression-free...
Ipilimumab - latest research news and features - Medical Xpress
Ipilimumab (also known as MDX-010 or MDX-101), marketed as Yervoy, is a drug used for the treatment of melanoma, a type of skin cancer. It is a U.S. Food and Drug Administration (FDA) approved ...
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in …
Sep 15, 2024 · In the nivolumab-plus-ipilimumab group, melanoma-specific survival at 10 years was 87% among patients with a depth of response of at least 80% and was 72% among patients with a depth of...
FDA Grants Fast Track Designation to UV1 Vaccine Combo in …
Feb 6, 2024 · The FDA has granted fast track designation to UV1, an investigational cancer vaccine, plus nivolumab (Opdivo) and ipilimumab (Yervoy) in the management of unresectable malignant pleural mesothelioma, according to a press release from Ultimovacs ASA, the developer of the vaccine. 1
Dual Immunotherapy Treatment Improves Progression-Free …
Jan 20, 2024 · The dual immunotherapy combination of nivolumab and ipilimumab reduced the risk of disease progression or death by 79% compared to chemotherapy with or without targeted therapies as first-line treatment in patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer.
FDA Approves Drug Combination for Treating Mesothelioma
Oct 2, 2020 · Today, the FDA approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adults with malignant pleural mesothelioma that cannot be removed by surgery.
Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade …
Aug 17, 2023 · Ninety-two eligible patients were randomly assigned in a 3:1 ratio to receive the combination of ipilimumab and nivolumab, or ipilimumab alone. The primary endpoint was progression-free...